Download the Full Shortlist Here

SPONSORED BY IN ASSOCIATION WITH 2020 & Shortlist best investor communication award breakthrough of the year award sponsored by Rothschild & Co. sponsored by RBC Capital Markets • AJ Bell plc • AO World plc • Grainger plc • AstraZeneca plc • Marshalls plc • BATM Advanced Communications Limited • UDG Healthcare plc • Oxford BioMedica plc • United Utilities Group plc • Reach plc • Volution Group plc • TT Electronics plc innovation in technology award CEO of the year award sponsored by Zeus Capital sponsored by Primary Bid/Research Tree • AstraZeneca plc • Brian Duffy/Watches of Switzerland Group plc • Clipper Logistics plc • Mike Norris/Computacenter plc • CMC Markets plc • Ian Page/Dechra Pharmaceuticals plc • Kainos Group plc • Duncan Penny/XP Power Limited • Ocado Group plc • Peter Pritchard/Pets at Home Group plc • TBC Bank Group plc • Nick Wilkinson/Dunelm Group plc transformation of the year award new company of the year award sponsored by Squire Patton Boggs sponsored by Link Group • Aveva Group plc • Bytes Technology Group plc • Avon Rubber plc • Conduit Holdings Ltd • Chemring Group plc • HeiQ plc • DWF Group plc • Ninety One plc • Premier Foods plc • Pensana plc • Xaar plc • THG Holdings plc fund manager award company of the year award sponsored by UBS sponsored by Liberum • James Baker/Chelverton Asset Management • Clipper Logistics plc • Rosemary Banyard/Downing • Electrocomponents plc • Georgina Brittain/J.P. Morgan Asset • Genus plc Management • Intermediate Capital Group plc • Anthony Cross/LionTrust Asset Management • Kainos Group plc • Richard Power/Octopus Investments • Treatt plc • Mike Savage/Killik & Co • Richard Watts/Jupiter Asset Management • Gervais Williams/Premier Miton Investors • Nick Williamson/Jupiter Asset Management • Ken Wotton/Gresham House.

Copy Link

Recommended publications

Exploring the Secrets of Success
people technolog siness Issue 35 In this issue Exploring the secrets of success 2 Business Insight GS-insight discusses some of the latest trends and Graham Charlton, CFO, Softcat opportunities in the international technology industry, the importance of company culture in business 5 Consulting Insight success and much more … Martin Smith, Executive Director, Sheffield Haworth Welcome to the 35th edition of GS-insight, fit and thereby de-risk the hiring process. Consulting Solutions the magazine of international technology Understandably, investors and Boards are sector Executive Search specialists Gillamor very keen to have a robust assessment of Stephens, part of Sheffield Haworth, the global the strengths and risks associated with 6 International Insight talent consulting and leadership advisory management teams and of their capability to Kelly Kinnard, VP Talent, firm. As a recruitment team, we are fortunate grow, change and adapt to achieve business Battery Ventures to work with companies at all stages of organ- objectives. isational and business development; from This issue of GS-insight explores a wide 8 Investment Insight university “spin-outs” requiring CEOs to help range of themes with leaders across our commercialise “bleeding edge” technology, Mark Boggett, CEO, industry sector. We discuss the importance Seraphim Space Capital through to privately owned and VC/PE of company culture and business growth with funded small-mid size businesses seeking Graham Charlton of Softcat and Russell Sloan the leaders to drive organic and acquisitive of Kainos, two of the most successful and 10 Non-Executive growth/internationalisation strategies to the fastest growing publicly listed technology Insight larger corporate entities hiring executives to businesses.
[Show full text]
Jefferies 2013 Global Healthcare Conference in London
Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
[Show full text]
Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
[Show full text]
Annual Report of Proxy Voting Record Date Of
ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 250 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Infrastructure plc TICKER: 3IN CUSIP: ADPV41555 MEETING DATE: 7/5/2018 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT RICHARD LAING AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT IAN LOBLEY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT PAUL MASTERTON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT DOUG BANNISTER AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT WENDY DORMAN AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: ELECT ROBERT JENNINGS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: RATIFY DELOITTE LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #11: AUTHORISE BOARD TO FIX REMUNERATION OF ISSUER YES FOR FOR AUDITORS PROPOSAL #12: APPROVE SCRIP DIVIDEND SCHEME ISSUER YES FOR FOR PROPOSAL #13: AUTHORISE CAPITALISATION OF THE ISSUER YES FOR FOR APPROPRIATE AMOUNTS OF NEW ORDINARY SHARES TO BE ALLOTTED UNDER THE SCRIP DIVIDEND SCHEME PROPOSAL #14: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #15: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR
[Show full text]
Parker Review
Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
[Show full text]
Introduction to Premier Foods January 2021 History and Introduction
Introduction to Premier Foods January 2021 History and Introduction 2 GROUP OVERVIEW Grocery (67% of sales) • Listed on the London Stock Exchange since 2004 • One of the UK’s largest food manufacturers • Manufactures, distributes, sells and markets a wide range of predominantly branded products in the ambient grocery sector • Market leading product portfolio including cakes, gravies, stocks, cooking sauces & accompaniments, Sweet Treats (28% of sales) desserts, soups and pot snacks • Operates from 16 sites in the UK International (5% of sales) Sales £847m EBITDA £153m 3 WE ARE ONE OF THE UK’s LEADING AMBIENT GROCERY SUPPLIERS 5.6 5.4 4.4 % Share 3.3 3.2 3.2 2.9 2.9 2.5 2.3 2.1 1.8 1.5 Mondelez Nestle Coca-Cola Mars PepsiCo Premier Britvic Heinz Pladis (UB) Kellogg's Unilever ABF Princes Foods Source: Kantar Worldpanel, 52 weeks ending 6 September 2020, excludes Foodservice and out of home 4 STRONG BRAND EQUITY Strong market shares and high household penetration Categories Brands Position Share Penetration Flavourings & Seasonings 1 44% 73% Quick Meals, Snacks & Soups 1 33% 47% Ambient Desserts 1 36% 59% Cooking Sauces & Accompaniments 1 16% 54% Ambient Cakes 1 24% 65% Sources: Category position & market share: IRI 52 w/e 26 September 2020; Penetration: Kantar Worldpanel 52 w/e 4 October 2020 5 PREMIER FOODS IS A VERY DIFFERENT BUSINESS TO 4 YEARS AGO A successful branded growth model with reduced leverage and de-risked pensions 2016 2020 Flat to marginally positive 14 consecutive quarters Trading sales growth UK sales growth Leverage 3.63x
[Show full text]
FT UK 500 2011 A-Z Company UK Rank 2011 3I Group 94 888 Holdings 485 Abcam 250 Aberdeen Asset Management 109 Admiral Group 72 A
FT UK 500 2011 A-Z UK rank Company 2011 3I Group 94 888 Holdings 485 Abcam 250 Aberdeen Asset Management 109 Admiral Group 72 Advanced Medical Solutions 488 Aegis Group 127 Afren 138 African Barrick Gold 118 African Minerals 131 Aggreko 69 Albemarle & Bond 460 Allied Gold 306 Amec 75 Amerisur Resources 426 Amlin 124 Anglo American 11 Anglo Pacific Group 327 Anglo-Eastern Plantations 370 Anite 445 Antofagasta 29 Aquarius Platinum 136 Archipelago Resources 346 Arm Holdings 42 Ashley (Laura) 476 Ashmore 112 Ashtead Group 206 Asian Citrus 263 Asos 171 Associated British Foods 41 Assura 449 Astrazeneca 12 Atkins (WS) 240 Aurelian Oil & Gas 334 Autonomy 76 Avanti Communications 324 Aveva 192 Avis Europe 326 Aviva 31 Avocet Mining 287 Axis-Shield 469 AZ Electronic Materials 199 Babcock International 117 Bae Systems 35 Bahamas Petroleum 397 Balfour Beatty 111 Barclays 16 Barr (AG) 289 Barratt Developments 197 BBA Aviation 209 Beazley 257 Bellway 216 Bellzone Mining 292 Berendsen 222 Berkeley 160 Betfair Group 202 BG Group 8 BHP Billiton 7 Big Yellow Group 308 Blinkx 344 Bodycote 259 Booker 213 Boot (Henry) 478 Borders & Southern Petroleum 378 Bovis Homes Group 268 Bowleven 220 BP 4 Brammer 351 Brewin Dolphin 319 British American Tobacco 9 British Land 61 British Sky Broadcasting 27 Britvic 210 Brown (N) 237 BT Group 28 BTG 235 Bunzl 107 Burberry 59 Bwin Party Digital Entertainment 223 Cable & Wireless Communications 181 Cable & Wireless Worldwide 158 Cairn Energy 49 Caledon Resources 380 Camellia 389 Cape 270 Capita 66 Capital & Counties Properties
[Show full text]
Annual Report 2016
Annual Report 2016 About Kainos Kainos is a digital services company, offering information technology products and services to clients in a range of markets, including government, healthcare and financial services. Kainos provides software design and development services and a complementary suite of software products in healthcare and automated testing. Kainos is now a global business with increasing scale, resilience, ambition and expertise. We’ve delivered over 35% compound growth in the past three years and we’re recognised as a continuing disruptive force in our core markets of government, healthcare and commercial industries. We’re increasingly trusted by our clients, including global organisations such as Diageo and Aviva, and by large UK government departments such as the Ministry of Justice. We provide them with digital technology solutions that help them conduct their business more efficiently. In healthcare, we’re working with Apple Inc. to develop genuinely new mobile applications that have the potential to change forever the way in which clinicians can help patients. In all of our services and products we strive to ensure that Kainos continues to serve the changing needs of customers. Just as we have gained the trust and respect of our clients, we are once again judged by our staff to be one of the best companies to work for. Our people remain our top priority, and we continue to invest in recruiting the best, and providing rewarding and enjoyable careers for them. Our business model is simple: we recruit the best people and encourage them to deliver exceptional services and products to customers. Everything we do is centred on this core principle, and it has served us well over time.
[Show full text]
Cboe UK Healthcare Sector Index BUKHLTH
Cboe UK Healthcare Sector Index BUKHLTH Page 1 August 2021 Cboe Exchange This sector represents products and services that are designed, developed, and utilized in the promotion of health and well-being, including medical services, health plans, medical devices, and biopharmaceuticals. The parent index is the Cboe UK All Companies (BUKAC). The index base level is 10,000 as of December 31st, 2010. This is a price return index. Objective The index is designed for use in the creation of index tracking funds, derivatives and as a performance benchmark. Investability Liquidity Transparency Availability Stocks are selected and Stocks are screened to Uses a transparent, rules-based Calculation is based on weighted to ensure that the ensure that the index is construction process. Index price and total return index is investable. tradable. Rules are freely available on the methodologies, both real cboe.com/europe/indices -time, intra-second and website. end of day. Statistics Index ISIN Ticker RIC Currency Cboe UK Healthcare Sector DE000SLA1DJ6 BUKHLTH .BUKHLTH GBP Cboe UK Healthcare Sector - net DE000SLA18F5 BUKHLTHN .BUKHLTHN GBP Volatility Volatility (1y) 0.1776 Returns(%) 1M 3M 6M YTD 1Y 3Y 5Y BUKHLTH 2.03 2.35 16.31 7.02 -2.85 13.78 17.14 BUKHLTHN 2.97 3.33 18.35 10.28 0.52 26.24 39.74 Top 5 Performers Country 1 month return % INDIVIOR PLC UNITED KINGDOM 17.70 MEDICLINIC INTERNATIONAL PLC UNITED KINGDOM 12.80 OXFORD BIOMEDICA PLC UNITED KINGDOM 11.38 PURETECH HEALTH PLC UNITED KINGDOM 8.77 VECTURA GROUP PLC UNITED KINGDOM 7.76 Historical Performance Chart 100% 80% 60% 40% 20% 0% 2011 2013 2014 2016 2017 2018 2020 2021 Cboe UK Healthcare Sector (GBP) Cboe UK All Companies (GBP) Cboe.com | ©Cboe | /CboeGlobalMarkets | /company/cboe © 2021 Cboe Exchange, Inc.
[Show full text]
Finn-Ancial Times Finncap Financials & Insurance Quarterly Sector Note
finn-ancial Times finnCap Financials & Insurance quarterly sector note Q3 2020 | Issue 9 Highlights this quarter: Elevated uncertainty and volatility have been hallmarks of the last 18 months, with Brexit, the UK General Election and more recently COVID-19 all contributing to the challenges that face investors wishing to carve out solid and stable returns amid these ‘unprecedented’ times. With this is mind, and simulating finnCap’s proven Slide Rule methodology, we found the highest quality and lowest value stocks across the financials space, assessing how the make-up of these lists changed over the period January 2019 to July 2020, tracking indexed share price performance over the period as well as movements in P/E and EV/EBIT valuations. The top quartile list of Quality companies outperformed both the Value list and the FTSE All Share by rising +2.5% over the period versus -5.4% for the All Share and -14.3% for Value stocks. Furthermore, the Quality list had protection on the downside in the market crash between February and March 2020, and accelerated faster amid the market rally between late March and July 2020. From high to low (January to March), Quality moved -36.3% against the Value list at -45.5%, while a move off the lows to July was +37.4% for Quality and +34.0% for Value. There was some crossover between the Quality and Value lists, with 7 companies of the top quartile (16 companies in total) appearing in both the Quality and Value lists. This meant that a) investors could capture what we call ‘Quality at Value’ (i.e.
[Show full text]
March 2018 1 MARKET UPDATE| HEALTHCARE
MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
[Show full text]
FTSE Factsheet
FTSE COMPANY REPORT Share price analysis relative to sector and index performance Duke Royalty DUKE Investment Banking and Brokerage Services — GBP 0.4125 at close 10 August 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 10-Aug-2021 10-Aug-2021 10-Aug-2021 0.45 140 140 1D WTD MTD YTD Absolute -2.4 -1.2 -1.8 35.2 130 130 0.4 Rel.Sector -2.4 -0.5 -3.6 25.9 Rel.Market -2.8 -1.7 -3.7 20.9 120 120 0.35 VALUATION 110 110 0.3 Trailing 100 100 Relative Price Relative Price Relative 0.25 PE -ve Absolute Price (local (local currency) AbsolutePrice 90 90 EV/EBITDA -ve 0.2 80 80 PB 2.0 PCF 28.1 0.15 70 70 Div Yield 4.6 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Aug-2020 Nov-2020 Feb-2021 May-2021 Aug-2021 Price/Sales -ve Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.2 90 90 90 Div Payout -ve 80 80 80 ROE -ve 70 70 70 Share Index) Share Share Sector) Share - 60 - 60 60 DESCRIPTION 50 50 50 40 40 The Company is a globally focused investment 40 RSI RSI (Absolute) 30 30 company specialising in diversified royalty investment.
[Show full text]